ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Medicenna Therapeutics Corporation (QX)

Medicenna Therapeutics Corporation (QX) (MDNAF)

1.2045
0.0745
( 6.59% )
Updated: 14:02:29

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.2045
Bid
1.18
Ask
1.21
Volume
6,990
1.15 Day's Range 1.21
0.2839 52 Week Range 2.20
Market Cap
Previous Close
1.13
Open
1.15
Last Trade
60
@
1.18
Last Trade Time
14:13:33
Financial Volume
$ 8,251
VWAP
1.1804
Average Volume (3m)
121,701
Shares Outstanding
76,925,289
Dividend Yield
-
PE Ratio
-5.08
Earnings Per Share (EPS)
-0.33
Revenue
-
Net Profit
-25.47M

About Medicenna Therapeutics Corporation (QX)

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Toronto, Ontario, Can
Founded
-
Medicenna Therapeutics Corporation (QX) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker MDNAF. The last closing price for Medicenna Therapeutics (QX) was $1.13. Over the last year, Medicenna Therapeutics (QX) shares have traded in a share price range of $ 0.2839 to $ 2.20.

Medicenna Therapeutics (QX) currently has 76,925,289 shares outstanding. The market capitalization of Medicenna Therapeutics (QX) is $86.93 million. Medicenna Therapeutics (QX) has a price to earnings ratio (PE ratio) of -5.08.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0055-0.4545454545451.211.3451.13731611.18967577CS
4-0.492-29.00088417331.69651.80.882237561.29017792CS
12-0.4055-25.18633540371.611.89150.881217011.41062264CS
26-0.8955-42.64285714292.12.20.881101491.50868903CS
520.8565246.1206896550.3482.20.28391091011.31465718CS
156-3.4655-74.20770877944.674.670.1581107691.20620638CS
2600.154514.71428571431.055.320.158950341.72587981CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AOLSAeolus Pharmaceuticals Inc (CE)
$ 0.005
(499,900.00%)
385
IPTKAS IP Tech Inc (CE)
$ 0.0018
(179,900.00%)
1,000
VIVEViveve Medical Inc (CE)
$ 0.0005
(49,900.00%)
23.11k
ECPNEl Capitan Precious Metals Inc (CE)
$ 0.0003
(29,900.00%)
80.5k
IDBHFIndustrias Bachoco SAB De CV (CE)
$ 0.0161
(16,000.00%)
600
FDVXFFenixOro Gold Corporation (CE)
$ 0.000001
(-100.00%)
6k
PLBLFAltus Copper Corporation (CE)
$ 0.000001
(-99.93%)
100
BZTGBuzz Technologies Inc (CE)
$ 0.000001
(-99.80%)
2.58M
ARBHArboreta Healthcare Inc (CE)
$ 0.000001
(-99.67%)
2k
APQTAppliqate Inc (CE)
$ 0.000001
(-99.50%)
4k
HMBLHUMBL Inc (PK)
$ 0.00025
(-16.67%)
300.36M
FUNRFunr (PK)
$ 0.0004
(300.00%)
173.35M
RDARRaadr Inc (PK)
$ 0.001
(-9.09%)
130M
BEGIBlackStar Enterprise Group Inc (PK)
$ 0.0008
(-42.86%)
105.57M
GRLFGreen Leaf Innovations Inc (PK)
$ 0.0001
(0.00%)
95.08M

MDNAF Discussion

View Posts
2H2 2H2 3 months ago
Big conference next week. Paris.

Oui oui!
👍️0
2H2 2H2 3 months ago
Bollies on daily are tightening up kids. Big conference coming up in sept
👍️0
2H2 2H2 4 months ago
Research-Capital analyst- $MDNAF buy rating & $4.5 TP

MDNA11 continue to demonstrate compelling efficacy:
2 patients #melanoma & #pancreatic treated with MDNA11 continue to demonstrate a complete response

Notably, both patients were previously treated with checkpoint inhibitors
👍️0
2H2 2H2 6 months ago
And more awesome results. 20x bagger here soon? Pc needs a new top line therapy, guess who?
👍️0
2H2 2H2 7 months ago
MDNAF is a presenter at ASCO. Huge news!
👍️0
2H2 2H2 8 months ago
Great presentation at ASCO
👍️0
Monksdream Monksdream 9 months ago
It is what they all say about stonks trading on Cromwell Coulson’s stonk market
👍️0
2H2 2H2 9 months ago
Relishing soon. This will be 10x current value this year
👍️0
Monksdream Monksdream 9 months ago
Delisted from Nasdaq
Gee, it sure is great to watch the price of a stock I bought at $400 a share advance to a 52=week high
👍️0
2H2 2H2 9 months ago
Getting legs here. Train leaving.
👍️0
axelvento axelvento 1 year ago
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
👍️0
Renee Renee 1 year ago
MDNA changed to MDNAF. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
Monksdream Monksdream 1 year ago
MDNA new 52 week low
👍️0
Monksdream Monksdream 1 year ago
MDNA new 52 week low
👍️0
Monksdream Monksdream 1 year ago
MDNA NEW 52 week low
👍️0
Investopotia Investopotia 3 years ago
Medicenna Therapeutics $MDNA highlighted in Midas Letter/BioPub interview: Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist
👍️0
EagleD EagleD 4 years ago
Going much higher. Double digits in a few months
👍️0
EagleD EagleD 4 years ago
Nice after hours action, Just made 20,000. Yadda Yadda Yadda.

Nobody is here listening to me. THis one is going to be a beast tho
👍️0
EagleD EagleD 4 years ago
FDA meeting Tuesday. Seems like we'll know sometime in October the results
👍️0
EagleD EagleD 4 years ago
This is my largest holding -- ever. Lots of value to be unveiled here in the coming months.
👍️0
Renee Renee 4 years ago
MDNA moved from the OTC to the Nasdaq:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
tykundegex tykundegex 6 years ago
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.

I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
👍️0
BioSpecialist BioSpecialist 7 years ago
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
👍️0